Biological Dressings Based on Natural Polymers

**Abstract**

The article presents a method for producing a IV generation hemostatic dressing in the form of powder consisted of fibrous, which ensures a high level of security in application. The dressing material was developed on the basis of natural polymers of the polysaccharide group such as chitosan and calcium sodium alginate in the form of micro- and nanofibrils. The dressing structure, utility properties and biocompatibility (cytotoxicity, irritation and sensitization) were studied.

**Key words**: wound dressing, polysaccharides, micro-fibrils, nano-fibrils, biocompatibility.

---

**Introduction**

Hemorrhage and neurological trauma are the main causes of death during the pre-hospital period in civilian and military trauma patients [1 - 3]. Approximately 20% of combat casualties are killed before reaching medical help or a medical facility [4]. Hemorrhage – uncontrolled bleeding, should be controlled as early and as effectively as possible. Competent hemorrhage control is very important and can theoretically save more human beings than any other measure. However, the best way to achieve this in challenging combat situations is not a simple task.

Alginate dressings are present in the form of nonwovens, plates or cord to prevent deep wounds [11]. Hemostatic activity is associated with calcium ions, which are released to the wound and accelerate the activation of platelets [12]. There are also known dressings prepared on the basis of chitin, chitosan and their derivatives [13 - 15]. Chitin and chitosan dressings are an important group of hemostatic dressings [16 - 18]. The hemostatic effect is based on direct adhesion, causing the physical sealing of the bleeding site. In addition, these dressings activate platelets, which accelerates the incorporation of red blood cells forming a clot [16 - 18]. Forms of chitosan hemostatic dressings are mostly patches or sponge made for controlling bleeding from small vessels. Although the chitosan used to design the above-mentioned specialised dressings accelerates fibrin formation and platelet aggregation, these dressings are not universal. Their usage is limited for various reasons, and it is repeatedly recommended to use compression during dressing application. The need for usage compression can cause the prolongation of bleeding control procedures, increasing the risk of infection and patient suffering. Therefore presently research is being conducted on the development of hemostatic wound dressings of the IV generation. Material of the IV generation require compression and to be possible to use at home, in the operating room and in combat conditions.

It seems that biopolymers are a suitable base for the construction of a new generation of hemostatic dressings [7 - 10]. From the group of biopolymers, algimian, collagen, chitin and its derivatives deserve special attention.
means rapid bleeding control and a high degree of safety during application. Examples of such materials are produced by
the American Company - Medical Sam - Celox™ - chitosan hemostytic dressing [19,20]. The form of pellets or foam
applied by the pressure applicator does not require the use of compression. This dressing is currently undergoing preclinical
and clinical studies [21].

For many years, research on the use of natural polymers for the construction of various types of dressing materials
has been carried out at the Institute of Biopolymers and Chemical Fibres, Lodz, Poland (IBWCh). The article presents
a method for producing domestic, IV generation hemostatic dressing in the form of powder based on a new utility
form of natural polymers - micro- and nanofibrids developed at IBWCh. The main objective of the study was to obtain
a “first aid” dressing exhibiting appropriate biological (hemostatic, biocompatible) properties and ensuring a high level
of security in application.

### Experimental

#### Materials

- Chitosan, Initial chitosan ChitoClear hcg 95, Mv=373kDa, DD=81%, Ash content=0.31%, Primex ehf Company,
  Iceland.
- Sodium alginate, Protanal LF 10/60FT, (FMC Company, England).

#### Methodology

**Preparation of dressing material in powder form**

For the preparation of dressing material in powder form, a chitosan/Na/Ca alginate compound was used in the form of
micro- and nanofibrids. The compound contained 80 wt.% chitosan and 20 wt.% Na/Ca alginate. The fibrids were prepared
by the wet mixing method using an in-line homogenizer - Dispax Reactor Labor-Pilot 2000/4 [22]. The polymer
forms obtained were dried by either freeze-drying or the spray-drying method.

The freeze-drying process was carried out using a laboratory lyophilizer - ALFA 2-4, (Martin Christ, Germany), in a time
span of 20 - 22 h and vacuum range of 0.01 - 0.042 mPa. The dried powder was ground using a M-20 (IKA, Germany)
universal mill.

The spray-drying process of micro- and nanofibrid suspension was carried out using a B-290 Mini Spray Dryer (Büchi, Swit-
zerland). A spray nozzle of Ø = 0,7 mm was used and the process parameters were as follows: feed rate 5 - 7 ml/min,
inlet air temperature 210 °C, outlet air temperature 94 - 96 °C, air flow rate in the aspirator 37 m3/h, and spray flow rate
357 l/h.

**Evaluation of dressing absorbency**

The evaluation of dressing absorbency was carried out in accordance with the standard PN-EN 13726-1: 2005 - “Test
methods for wound dressings. Part 1: Aspects of absorbency. The research was carried out at the Institute of Security
Technology MORATEX, Lodz, Poland.

**Structure assessment of dressing in powder form**

The structure of the dressing in powder form was assessed using a scanning electron microscope - Quanta 200 (FEI Co.,
USA). Measurement of the powder particle dimensions was made using AnalySIS Docu software (Soft Imaging System)
adapted to the Quanta environment.

**Bulk and tangled density of dressing in powder form**

Analyses were carried out according to European Pharmacopoeia 8.0, Chapter 2.9.34 and 2.9.36. Analyses of the pow-
ders, consistent with the classification by Carr, included bulk density, tangled densi-
ty, the compressibility index and Hausner ratio. The dependence between the angle of repose, the compressibility index and
Hausner ratio is presented in Table 1.

**Sterilisation of dressing**

Sterilisation was made at the Institute of Applied Radiation Chemistry, Lodz University of Technology by irradiating
the samples with a 25 kGy dose of γ rays.

**Cytotoxicity testing of the dressing**

The study was carried out according to procedures described in the following standards: ISO 10993-5: 2009 Biological
evaluation of medical devices - Part 5: Tests in vitro cytotoxicity and ISO 10993-12: 2009 Biological evaluation of medi-
cal devices - Part 12: Preparation sample and reference materials. Research was performed using extracts from tested and
control materials. The research was carried out at the Department of Experimental Surgery and Biomaterials Research,
Medical University, Wroclaw, Poland.

### Table 1. Dependence between the angle of repose, compressibility index and Hausner ratio*, *European Pharmacopoeia 8.0, Chapter 2.9.36.

| Flow property       | Angle of repose, degrees | Compressibility index, % | Hausner ratio |
|---------------------|--------------------------|--------------------------|---------------|
| Excellent           | 25 - 30                  | 1 - 10                   | 1.00 - 1.11    |
| Good                | 31 - 35                  | 11 - 15                  | 1.12 - 1.18    |
| Fair (aid not needed)| 36 - 40                  | 16 - 20                  | 1.19 - 1.25    |
| Passable (may hang up)| 41 - 45                  | 21 - 25                  | 1.26 - 1.34    |
| Poor (must agitate, vibrate)| 46 - 55              | 26 - 31                  | 1.35 - 1.45    |
| Very poor           | 56 - 65                  | 32 - 37                  | 1.46 - 1.59    |
| Very, very poor     | > 66                     | > 38                     | > 1.60         |

### Table 2. Qualitative morphological grading of cytotoxicity of extracts*, * ISO 10993-5: 2009 standard.

| Grade | Reactivity | Conditions of all cultures |
|-------|------------|---------------------------|
| 0     | None       | Discrete intracytoplasmatic granules, no cell lysis, no reduction of cell growth |
| 1     | Slight     | Not more than 20% of the cells are round, loosely attached and without intracytoplasmatic granules, or show changes in morphology; occasional lysed cells are present; only slight growth inhibition observable |
| 2     | Mild       | Not more than 50% of the cells are round, devoid of intracytoplasmatic granules, no extensive cell lysis, not more than 50% growth inhibition observable |
| 3     | Moderate   | Not more than 70% of the cell layers contain rounded cells or are lysed; cell layers not completely destroyed, but more than 50% growth inhibition observable |
| 4     | Severe     | Nearly complete or complete destruction of the cell layers |

### Table 3. Primary irritation index (PII)*, Part - 10: Tests for irritation and skin sensitisation. *Standard: ISO 10993-10.

| Mean score | Response category |
|------------|-------------------|
| 0.0 - 0.4  | negligible        |
| 0.5 - 1.9  | slight            |
| 2.0 - 4.9  | moderate          |
| 5.0 - 8.0  | severe            |
Morphological changes in cells were evaluated under an inverted phase contrast microscope according to the criteria given in Table 2.

Assessment of irritant properties
A test was performed according to Standard: ISO 10993-10:2011 Biological evaluation of medical devices - Part 10: Tests for irritation and skin sensitisation. The research was carried out at the Department of Experimental Surgery and Biomaterials Research, Medical University Warsaw, Poland.

A test of irritant properties was conducted by the single exposure method on albino rabbits of the New Zealand White breed, of both sexes, weighing 3.3 - 3.9 kg. Dressing samples were put on the skin for a period of 24 hours. For each test sample and control sample the primary irritation index was determined using results at 24, 48 and 72 h (Table 3).

Table 3. Assessment of bulk density of dressings in powder form; a) SEM of P/R/Chit/AlgNa-Ca dressing in powder after spray-drying, b) SEM of P/L/Chit/AlgNa-Ca dressing in powder after freeze-drying.

| Material                  | Bulk density, kg/m³ | Tapped density, kg/m³ | Hausner ratio |
|---------------------------|---------------------|-----------------------|---------------|
| P/L/Chit/AlgNa-Ca         | 85                  | 117                   | 1.38          |
| P/L/Chit/AlgNa-Ca/S       | 89                  | 126                   | 1.43          |
| P/R/Chit/AlgNa-Ca         | 132                 | 188                   | 1.42          |
| P/R/Chit/AlgNa-Ca/S       | 142                 | 188                   | 1.66          |

Assessment of allergenic properties
A test was performed according to Standard: ISO 10993-10 Biological evaluation of medical devices - 10: Tests for irritation and skin sensitisation. The assessment of skin sensitisation was carried out by the closed patch - Buehler method, chosen due to the future place of dressing contact. The research was carried out at the Department of Experimental Surgery and Biomaterials Research, Medical University, Warsaw, Poland.

Evaluation of allergenic properties was carried out on albino guinea-pigs of both sexes, with an initial body weight of 340 - 400 g.

Results and discussion
Structure assessment of dressings in powder form
The structure assessment of the dressing material showed that the method of drying selected made it possible to obtain polymeric materials in powder form with a high surface area and dimensions of fibrils in the micro- and nanometric range. As a result of spray drying, a dressing material in powder form was obtained in which the fibrils were rolled up to form the shapes of pellets having a diameter of 0.9 - 6.0 µm. (Figure 1). The reason for this is believed to be in the specifics of spray drying, wherein the aqueous suspension of fibrils is sprayed into a hot drying medium. In the case of freeze-drying, a powder with fewer regular particles of 10-60 µm dimensions was obtained.

Assessment of bulk density of dressings in powder form
The bulk density of the dressing materials was measured. In the case of dressings in powder form, this parameter is extremely important as it allows to determine the capacity of the powder to settle on a wound. Prototypes of dressings manufactured by freeze-drying (P/L/Chit/AlgNa-Ca) and spray-drying (P/R/Chit/AlgNa-Ca) were tested before and after irradiation sterilization.

The results obtained showed that the powders developed are characterised by a Hausner ratio of 1.38 - 1.66. These parameter values indicate a high ability of the powder to settle, which is a very advantageous feature in terms of dressing applicability since the powder is held in the place of the intended operation and is not easy to flow. The results obtained also showed that the sterilisation process did not affect, in a significant manner, the test parameters determining the bulk density of the powders investigated.

Assessment of utility properties of dressings in powder form
The medical devices designed must meet a number of requirements defined by the relevant Directive 93/42/EEC harmonised standards. One of the requirements to be met by dressings are the appropriate utility properties, including the ability to absorb liquids. Determination of this parameter in a laboratory enables the assessment of dressing applicability to abundantly or moderately exuding wounds. Powders developed by either spray-drying or freeze-drying were tested. As a comparison, medical dressings in the form of a powder under the trade names Celox™ and QuikClot ACS+™ were used. Dressings subjected to radiation sterilisation were evaluated.

The study showed that the wound dressings prepared in the form of a powder obtained by freeze-drying (P/L/Chit/AlgNa-Ca) and spray-drying (P/R/Chit/AlgNa-Ca) show good absorption properties. The values of the parameter in both dressings were at a similar level, reaching approx. 8 g liquid/1 g dressing. The ability of the dressings tested to absorb liquids as compared to commercial dressing Celox™ was twice lower, and
in comparison with QuikClot ACS\textsuperscript{TM} it was significantly higher (Table 5).

### Assessment of biocompatibility of dressings in powder form

Dressings developed in the form of powders were subjected to in vitro and in vivo evaluation of biological properties. The studies included both an assessment of hemocompatibility and hemostatic properties of the dressing in vitro \cite{23, 24} and an assessment of biocompatibility in vitro and in vivo (cytotoxicity, irritation and allergisation properties).

### Cytotoxicity assessment

Evaluation of the cytotoxic effect of dressings obtained from the chit/AlgNa-Ca compound by freeze-drying and spray-drying was performed on L 929 mouse fibroblasts using the MTT test. The samples for tests were radiation sterilized. Evaluation of changes in the culture and cell viability was carried out after 24, 48 and 72 h of contact with the primary extracts of samples tested and their serial dilutions of 1:2, 1:4 and 1:8. The commercial dressing Celox\textsuperscript{TM} was a reference sample.

The study showed that the primary extract of sterile dressing (P/L/Chit/AlgNa-Ca) in powder form obtained by freeze-drying showed no cytotoxic effect after 24 h. After 48 and 72 h the toxic effect culminated in the decreased viability of cells as compared to the blank (67\% and 58\%, respectively). Diluted (1:2, 1:4 and 1:8) extracts did not show any cytotoxic effect at any period of the study (Table 6). The primary extract of sterile dressing (P/R/Chit/AlgNa-Ca) in powder form obtained by spray-drying showed no cytotoxic effect after 24 and 48 h. After 72 h the toxic effect culminated in the decreased viability of cells as compared to the blank (70\%). Diluted (1:2, 1:4 and 1:8) extracts did not show any cytotoxic effect at any period of the study (Table 6).

In the case of Celox\textsuperscript{TM} dressing it was not possible to assess cell viability due to the fact that during dissolution the sample turned into gel. Toxicity of the primary extract and 1:2 diluted extract was carried out only to assess the changes in the cultures. The toxicity of Celox\textsuperscript{TM} 1:4 and 1:8 diluted extracts was assessed on the basis of changes in the culture and cell viability.

The primary extract of Celox\textsuperscript{TM} dressing showed no cytotoxic effect after 24 h. After 48 and 72 h the toxic effect culminated in a change in the culture of the 3rd degree. Diluted (1:2, 1:4 and 1:8) extracts showed no cytotoxic effect after 24 h. For the 1:2 diluted extract after 48 h, and for 1:2 and 1:4 diluted extracts after 72 h, the cytotoxic effect culminated in changes in the cultures of the 3rd degree and decreased cell viability as compared to the blank (Table 6).

### Assessment of irritation and allergization

In vivo studies were performed only on Chit/AlgNa-Ca dressing in powder form obtained by spray-drying due to the fact

---

**Table 6. Assessment of cytotoxic effect of Chit/AlgNa-Ca powder dressings obtained by freeze-drying and spray-drying.**

| Sample          | Extract  | Cell viability, % | Degree of change in culture | Cytotoxic effect |
|-----------------|----------|-------------------|----------------------------|-----------------|
| Negative sample | 100%     | 93.38             | 0                          | none            |
| Positive sample SLS | 0.075 mg/ml | 80.93             | 1                          | none            |
|                 | 0.1 mg/ml | 3.3               | 3                          | +               |
|                 | 0.15 mg/ml | 24.9              | 4                          | +               |
|                 | 0.2 mg/ml | 17.9              | +                          |                 |
| P/L/Chit/AlgNa-Ca | Primary    | 87.25             | 0                          | none            |
|                 | 50%       | 87.20             | 0                          | none            |
|                 | 25%       | 86.68             | 0                          | none            |
|                 | 12.5%     | 91.35             | 0                          | none            |
| P/R/Chit/AlgNa-Ca | Primary    | 88.83             | 0                          | none            |
|                 | 50%       | 89.99             | 0                          | none            |
|                 | 25%       | 94.09             | 0                          | none            |
|                 | 12.5%     | 103.6             | 0                          | none            |
| Celox\textsuperscript{TM} | Primary    | Not assessed      | 2                          | +               |
|                 | 50%       | Not assessed      | 2                          | +               |
|                 | 25%       | 92.7              | 0                          | none            |
|                 | 12.5%     | 101.8             | 0                          | none            |
| Negative sample | 100%     | 107.27            | 0                          | none            |
| Positive sample SLS | 0.075 mg/ml | 66.28             | 2                          | none            |
|                 | 0.1 mg/ml | 20.46             | 4                          | +               |
|                 | 0.15 mg/ml | 14.6              | 4                          | +               |
|                 | 0.2 mg/ml | 10.23             | 4                          | +               |
| P/L/Chit/AlgNa-Ca | Primary    | 66.56             | 0                          | +/−             |
|                 | 50%       | 76.15             | 0                          | none            |
|                 | 25%       | 94.2              | 0                          | none            |
|                 | 12.5%     | 95.56             | 0                          | none            |
| P/R/Chit/AlgNa-Ca | Primary    | 79.73             | 0                          | none            |
|                 | 50%       | 81.13             | 0                          | none            |
|                 | 25%       | 93.91             | 0                          | none            |
|                 | 12.5%     | 98.77             | 0                          | none            |
| Celox\textsuperscript{TM} | Primary    | Not assessed      | 3                          | +               |
|                 | 50%       | Not assessed      | 3                          | +               |
|                 | 25%       | 89.1              | 2                          |none             |
|                 | 12.5%     | 94.2              | 2                          | none            |
| Negative sample | 100%     | 94.8              | 0                          | none            |
| Positive sample SLS | 0.075 mg/ml | 56.39             | 3                          | +               |
|                 | 0.1 mg/ml | 22.49             | 4                          | +               |
|                 | 0.15 mg/ml | 13.69             | 4                          | +               |
|                 | 0.2 mg/ml | 14.43             | 4                          | +               |
| P/L/Chit/AlgNa-Ca | Primary    | 57.57             | 1                          | +/−             |
|                 | 50%       | 70.66             | 0                          | none            |
|                 | 25%       | 86.62             | 0                          | none            |
|                 | 12.5%     | 80.77             | 0                          | none            |
| P/R/Chit/AlgNa-Ca | Primary    | 69.68             | 0                          | +/−             |
|                 | 50%       | 87.56             | 0                          | none            |
|                 | 25%       | 96.08             | 0                          | none            |
|                 | 12.5%     | 99.58             | 0                          | none            |
| Celox\textsuperscript{TM} | Primary    | Not assessed      | 3                          | +               |
|                 | 50%       | Not assessed      | 3                          | +               |
|                 | 25%       | 68.56             | 2                          | +               |
|                 | 12.5%     | 81.92             | 2                          | none            |
that the cytotoxicity tests showed no significant effect of the method of powder preparation on the cell culture. The commercial dressing Celox™ was a reference sample.

Irritation and allergisation tests were conducted through direct contact with the skin of animals. Based on the test results, it was found that dressings in the form of a powder made of the chitosan/alginate Na-Ca complex as well as commercial dressing Celox™ do not irritate the animals’ skin. The difference between the average scores for tested and reference dressings was zero. Also in the case of allergization tests none of the test animals showed an allergic reaction. The animals’ skin in the application site of both the examined dressing and reference dressing Celox™ had a normal appearance. The gender of the animals had no effect on the skin reaction. Both groups of treated and control animals showed normal weight gain.

Conclusions

1. Based on chitosan/alginate Na-Ca complex in the form of micro- and nanofibrils (chitosan-80% algNa-Ca-20%), the prototypes of dressing materials in the form of powder were prepared using freeze-drying and spray-drying methods.

2. Chit/algNa-Ca dressings developed in powder form obtained by freeze-drying and spray-drying show good absorption properties (approx. 8g liquid/1g dressing) and a high ability of the powder to settle in the application site.

3. Dressings developed in powder form showed no cytotoxicity in in vitro tests and no irritation and allergisation to the skin in vitro tests, which proves that they meet all the requirements in terms of biocompatibility for this type of medical device.

Acknowledgement

The research was carried out within a project contained in The Programme of Applied Research No PBS1/B7/5/2012 sponsored by the National Centre of Research and Development.

References

1. Committee on fluid resuscitation for combat casualties. Fluid resuscitation: state of the science for treating combat casualties and civilian injuries. Report of the Institute of Medicine. National Academy Press; Washington, DC, 1999, pp 1–7.
2. Wedmore JG, McManus A E, Pusateri J B, Holcomb A special report on the chitosan based hemostatic dressing: experience in current combat operations. J Trauma 2006;60(3): 655-8.
3. Evans J A, Wessem K J P, McDougall D, Lee K A, Lyons T, Balogh Z J. Epidemiology of Traumatic Deaths: Comprehensive Population-Based Assessment. World Journal of Surgery 2009; 34, 1: 158-163.
4. Bellamy RF. The cause of death in conventional land warfare: implications for combat casualty care research. Milit Med 1984; 149: 55–62.
5. Alam H B, Burris D, DaCorta J A and Rhee P. Hemorrhage Control in the Battlefield: Role of New Hemostatic Agents. Military Medicine 2005; 170, 1: 63 - 69.
6. Samudrala S. Topical Hemostatic Agents in Surgery: A Surgeon's Perspective. AORN 2008; 88, 3: S2-S11.
7. Struszczyk M H and Olejnik M. Obecne i przyszłe zapotrzebowanie rynku na włościennicze wyroby medyczne. Techniczne Wyroby Włościennicze 2010; 19-25.
8. The EU market for wound care and wound closure products, CBI Market Survey, 2009, http://www.icci.com.pk/data/downloads/10/1169838317_1.pdf [2012-03-02].
9. US Markets for Wound Management Products, Medtech Insight, RP-181303.
10. All Change in the Advanced Wound Care Market 2009. A complete guide to this dynamic market sector, Espicom Business Intelligence Ltd, May 2009.
11. Budynek M and Nowacki C. Wiedzka o opatrunkach, Łódź, 1999.
12. Willi P and Sharma Ch P. Chitosan and Alginate Wound Dressings: A Short Review. Trends Biomater. Artif. Organs 2004; 18(1): pp 18-23.
13. Dai T, Tanaka M and Huang YY R. Hamblin Chitosan preparations for wounds and burns: antimicrobial and wound-healing effects. Expert Rev Anti Infect Ther 2011; 9(7): 857–79.
14. Stephen-Haynes J, Gibson E, Greenwood M. Chitosan: a natural solution for wound healing. JCN 2014, 28, 1: 50-53.
15. Anitha A S. Sowmya P T, Sudheesh Kumar S, Deepthi K P, Chennazhi H, Ehrlich M, Turkan R. Jayakumar Chitin and chitosan in selected biomedical applications. Progress in Polymer Science2014; 39, 9: 1644–1667.
16. Muzzarelli R A A. Chitins and chitosans for the repair of wounded skin, nerve, cartilage and bone. Carbohydrate Polymers 2009; 76: 167–182.
17. http://www.trends-in-medicine.com/Oct2003/Closure103p.pdf, Hemorrhage Control in the Battlefield: Role of New Hemostatic Agents. MILITARY MEDICINE 2005; 170, 1-63.
18. Fischer T H, Connolly R, Thatte H S, Schwartzberg S S. Comparison of Structural and Hemostatic Properties of the poly-N-acetylglucosamineSyevex Patch with Products Containing Chitosan. Microscopy Research and Technique 2004; 63(3): 168-174.
19. Millner R W J, Lockhart A S, Alexiou Ch. A New hemostatic agent:initial Life-saving experience with Celox (chitosan) In cardiothoracic surgery. Ann. Thorac. Surg. 2009; 87, 13-14.
20. Gogel B, Burgert J, Cooley B, et. All. The effects of bleed-arrest, Celox, and trauma-dex on hemorrhage control in a porcine model. J. of Surgical Research 2010; 164: 125-129.
21. http://kopalniawiedzy.pl/opatrunk-chitosan-rana-krew-wypadek-ofiara-zolnierz.-9127.html
22. A method for producing fibrils containing chitosan. PL 214 380, 2008.
23. Kucharska M, Wiśniewska-Wrona M, Brzoza-Malczewska C, Struszczyk M H, Cichecka M, Wilbik-Halga B, Rybak Z, Szymonowicz M, Paluch D, Guźinska K, Kaźmierczak D. Haemostatic, resorbable dressing of natural polymers-HEMOGUARD, In: Progress on Chemistry and Application of Chitin and Its Derivatives, edited by M. Jaworska, vol. XX, Polish Chitin Society, 2015, p.130, DOI: 10.15259/PCACD.20.28.
24. Szymonowicz M, Kucharska M, Wiśniewska-Wrona M, Rybak Z. Evaluation of the hemostatic properties of the resorbable wound dressings in contact with blood in vitro. Acta of Bioengineering and Biomechanics DOI 10.5277/abbi, ISSN: 1509-409X

Received 16.05.2016  Reviewed 02.12.2016

FIBRES & TEXTILES in Eastern Europe 2016, Vol. 24, 6(120)